Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
galiximab t-lymphocyte activation antigen cd80 biotech NA drugbank , DGIDB Disease[MeSHID:D004194]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Rheumatoid Arthritis[MeSHID:D001172]
Malignant neoplasm of prostate[MeSHID:D011471]
Lymphoma[MeSHID:D008223]
Neoplasm Metastasis[MeSHID:D009362]
Bone Tissue[MeSHID:D001842]
Multiple Myeloma[MeSHID:D009101]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 47.74 investigational antibody,inhibitor
galiximab activation b7-1 antigen NA Successful target TTD , DGIDB Disease[MeSHID:D004194]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Rheumatoid Arthritis[MeSHID:D001172]
Malignant neoplasm of prostate[MeSHID:D011471]
Lymphoma[MeSHID:D008223]
Neoplasm Metastasis[MeSHID:D009362]
Bone Tissue[MeSHID:D001842]
Multiple Myeloma[MeSHID:D009101]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 47.74 phase 2 unknown
galiximab activation b7-1 antigen NA Successful target TTD , DGIDB Disease[MeSHID:D004194]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Rheumatoid Arthritis[MeSHID:D001172]
Malignant neoplasm of prostate[MeSHID:D011471]
Lymphoma[MeSHID:D008223]
Neoplasm Metastasis[MeSHID:D009362]
Bone Tissue[MeSHID:D001842]
Multiple Myeloma[MeSHID:D009101]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 47.74 phase 2 inhibitor
galiximab t-lymphocyte activation antigen cd80 biotech NA drugbank , DGIDB Disease[MeSHID:D004194]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Rheumatoid Arthritis[MeSHID:D001172]
Malignant neoplasm of prostate[MeSHID:D011471]
Lymphoma[MeSHID:D008223]
Neoplasm Metastasis[MeSHID:D009362]
Bone Tissue[MeSHID:D001842]
Multiple Myeloma[MeSHID:D009101]
Psoriasis[MeSHID:D011565]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 47.74 investigational antibody
click here to return to the previous page